Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.45M | 81.73M | 74.79M | 62.90M | 54.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.45M | 81.73M | 74.79M | 62.90M | 54.12M |
| Cost of Revenue | 50.88M | 51.57M | 64.62M | 53.31M | 56.39M |
| Gross Profit | 63.57M | 30.16M | 10.17M | 9.59M | -2.28M |
| SG&A Expenses | 76.22M | 72.84M | 69.50M | 65.62M | 64.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 127.10M | 124.41M | 134.12M | 118.92M | 121.17M |
| Operating Income | -12.65M | -42.67M | -59.33M | -56.03M | -67.05M |
| Income Before Tax | -12.74M | -41.19M | -60.34M | -54.84M | -69.57M |
| Income Tax Expenses | 20.00K | 39.00K | -72.00K | -84.00K | 85.00K |
| Earnings from Continuing Operations | -12.76M | -41.23M | -60.27M | -54.75M | -69.65M |
| Earnings from Discontinued Operations | -- | -- | 4.00K | -59.00K | -757.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.76M | -41.23M | -60.26M | -54.81M | -70.41M |
| EBIT | -12.65M | -42.67M | -59.33M | -56.03M | -67.05M |
| EBITDA | 1.37M | -29.87M | -47.24M | -44.79M | -56.71M |
| EPS Basic | -0.14 | -0.47 | -0.73 | -0.70 | -0.91 |
| Normalized Basic EPS | -0.09 | -0.29 | -0.44 | -0.44 | -0.56 |
| EPS Diluted | -0.14 | -0.47 | -0.73 | -0.70 | -0.91 |
| Normalized Diluted EPS | -0.09 | -0.29 | -0.44 | -0.44 | -0.56 |
| Average Basic Shares Outstanding | 88.95M | 88.36M | 83.11M | 77.78M | 77.50M |
| Average Diluted Shares Outstanding | 88.95M | 88.36M | 83.11M | 77.78M | 77.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |